Perrigo Company plc announced it has launched its AB rated abbreviated new drug application referencing Solaraze® Gel, 3% (diclofenac sodium gel, 3%). Solaraze® Gel, 3% is indicated for the topical treatment of actinic keratoses. Annual market sales for Solaraze® Gel, 3% for the 12 months ending September 2018 were approximately $31 million as measured by IQVIA™. Diclofenac sodium gel, 3% was developed through a pharmaceutical development partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. The product is manufactured by Perrigo and shipping to customers has commenced.